Zum Hauptinhalt springen
xMedica

NCT07636590ClinicalTrials.gov

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

A Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Beobachtend500 Teilnehmende gesucht21 Studienzentren1 Land

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 18 days after the recorded start)First posted 2026-06-09; recorded start 2026-05-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Claris Biotherapeutics, Inc.)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 500 participants (target), run at 21 sites.

How this score is built
  • Enrolment26/40

    500 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale1/10

    Claris Biotherapeutics, Inc. has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Erkrankungen

  • Limbal Stem Cell Deficiency

Eignung

Eignung
GeschlechtAlle
Alter12 Years – 99 Years
Gesunde FreiwilligeNein
StichprobenverfahrenPROBABILITY_SAMPLE

Studienpopulation

Adult and adolescent subjects with qualifying LSCD

Eignung im Wortlaut des Registers

Inclusion Criteria: * A photopic BCVA in the prospective study eye(s) of ≤ 70 letters at the Screening and Day 1 visits AND a change of ≤ 10 letters in photopic BCVA at Day 1 compared to the Screening Visit * Qualifying LSCD diagnosis in the study eye(s) prior to enrollment at Day 1 * Written confirmation that exclusions on retinal findings are met in the study eye(s) prior to enrollment at Day 1 * Inflammation associated with LSCD or other non-infectious inflammation (e.g., dry eye, ocular rosacea, and blepharitis) that will not interfere with the subject's participation in the opinion of the investigator is permitted. Exclusion Criteria: * Any active ocular infection in either eye at either the Screening or Day 1 visits * Active sterile iritis or uveitis in either eye at Screening or Day 1 visits * Screening visit retinal exam finding, in the opinion of the investigator, that would limit potential for visual acuity gain in the study eye(s) Note: Other inclusion/exclusion criteria apply.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypBeobachtend
PhaseIm Registereintrag nicht angegeben
ZuteilungIm Registereintrag nicht angegeben
InterventionsmodellIm Registereintrag nicht angegeben
Primäres ZielIm Registereintrag nicht angegeben
VerblindungIm Registereintrag nicht angegeben
Teilnahme500 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Claris Biotherapeutics, Inc. Sponsor

Studienarme und Interventionen

  • Non-interventional

    No product administration.

Interventionen

  • Sonstige Non-interventional

    Non-interventional

Endpunkte

  1. Primärer Endpunkt

    Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes

    Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires

    Zeitrahmen Screening through Week 84

  2. Primärer Endpunkt

    Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)

    Change in photophobic BCVA

    Zeitrahmen Screening through Week 84

  3. Primärer Endpunkt

    Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)

    Change in low-luminance BCVA

    Zeitrahmen Screening through Week 84

  4. Primärer Endpunkt

    Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)

    Change in low-contrast BCVA

    Zeitrahmen Screening through Week 84

  5. Primärer Endpunkt

    Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)

    Change in contrast sensitivity (Pelli-Robson)

    Zeitrahmen Screening through Week 84

  6. Primärer Endpunkt

    Natural Progression of LSCD as Assessed by Anatomical/Structural Changes

    Change in area of central cornea conjunctivalization

    Zeitrahmen Screening through Week 84

  7. Sekundärer Endpunkt

    Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)

    Changes (onset, improvement, or worsening) in corneal sensitivity

    Zeitrahmen Screening through Week 84

  8. Sekundärer Endpunkt

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)

    Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry

    Zeitrahmen Screening through Week 84

  9. Sekundärer Endpunkt

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)

    Changes (onset, improvement, or worsening) in epithelial defect frequency

    Zeitrahmen Screening through Week 84

  10. Sekundärer Endpunkt

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)

    Changes (onset, improvement, or worsening) in Palisades of Vogt crypts

    Zeitrahmen Screening through Week 84

  11. Sekundärer Endpunkt

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)

    Changes (onset, improvement, or worsening) in epithelial and total corneal thickness

    Zeitrahmen Screening through Week 84

  12. Sekundärer Endpunkt

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)

    Changes (onset, improvement, or worsening) in pannus

    Zeitrahmen Screening through Week 84

  13. Sekundärer Endpunkt

    Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures

    Changes (onset, improvement/resolution, or worsening) of an existing condition

    Zeitrahmen Screening through Week 84

Daten

Daten
Startdatum22. Mai 2026 (tatsächlich)
Primärer Abschluss1. März 2028 (geschätzt)
Abschluss1. März 2028 (geschätzt)
Erstveröffentlichung9. Juni 2026 (tatsächlich)
Zuletzt aktualisiert18. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtNovember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

21 Studienzentren rekrutieren

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Claris Investigative SiteCarmelIndianaRekrutiert
Claris Investigative SiteCranberry TownshipPennsylvaniaRekrutiert
Claris Investigative SiteDraperUtahRekrutiert
Claris Investigative SiteHuntington BeachCaliforniaRekrutiert
Claris Investigative SiteIndianapolisIndianaRekrutiert
Claris Investigative SiteKansas CityMissouriRekrutiert
Claris Investigative SiteLa JollaCaliforniaRekrutiert
Claris Investigative SiteLos AngelesCaliforniaRekrutiert
Claris Investigative SiteLouisvilleKentuckyRekrutiert
Claris Investigative SiteMinnetonkaMinnesotaRekrutiert
Claris Investigative SiteNorfolkVirginiaRekrutiert
Claris Investigative SiteOverland ParkKansasRekrutiert
Claris Investigative SitePalisades ParkNew JerseyRekrutiert
Claris Investigative SitePortlandOregonRekrutiert
Claris Investigative SiteRockville CentreNew YorkRekrutiert
Claris Investigative SiteSan AntonioTexasRekrutiert
Claris Investigative SiteSioux FallsSouth DakotaRekrutiert
Claris Investigative SiteSmyrnaTennesseeRekrutiert
Claris Investigative SiteSouth DartmouthMassachusettsRekrutiert
Claris Investigative SiteTampaFloridaRekrutiert
Claris Investigative SiteWichitaKansasRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 18. November 2026

    Studienzentrum hinzugefügt

    13 sites added (21 total)

    821

  2. 6. August 2026

    Studienzentrum hinzugefügt

    6 sites added (8 total)

    28